Grade: Pharmaceutical Grade

Factory Location: Shandong

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Prasugrel with CAS 150322-43-3 is a platelet inhibitor for acute coronary syndromes planned for percutaneous coronary intervention.

Prasugrel (CAS 150322-43-3), Prasugrel is a prodrug and is rapidly metabolized to a pharmacologically active metabolite and inactive metabolites. The active metabolite has an elimination half-life of about 7 hr (range 2–15 hr). Healthy subjects, patients with stable atherosclerosis, and patients undergoing PCI show similar pharmacokinetics.

The product above are not for sales where the patents are applicable and still valid.